Physician profile
Munish Loomba
NPI 1679579817
$9,823.55
in general payments reported to CMS, 2019-2025
28 companies · $850 in 2025
The $850 reported for 2025 was more than what 93% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,678 · 2020: $220 · 2021: $720 · 2022: $3,808 · 2023: $738 · 2024: $808 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,306 · Travel and Lodging: $90.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,306.15 |
| Travel and Lodging | $90.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,647.95 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, Superion Indirect Decompression System |
| Abbott Laboratories | $1,489.32 | 2019-2025 | Proclaim |
| Medtronic, INC. | $1,124.07 | 2022-2024 | Intellis Adaptivestim |
| Medtronic USA, INC. | $924.85 | 2019 | |
| Spinal Simplicity, LLC | $922.58 | 2022 | |
| Spr Therapeutics, INC | $506.25 | 2022-2023 | Sprint Pns System |
| Abbvie INC. | $404.28 | 2022-2025 | |
| Nevro Corp. | $337.82 | 2019-2024 | Senza |
| Scilex Pharmaceuticals INC. | $210.07 | 2019-2024 | Ztlido |
| Pfizer INC. | $205.73 | 2019-2025 | |
| Globus Medical, INC. | $184.27 | 2025 | Senza, Vyrsa V1 |
| Painteq LLC | $161.98 | 2023-2024 | Painteq |
| Si-Bone, INC. | $136.63 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $119.48 | 2022 | |
| Stryker Corporation | $67.52 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $44.73 | 2025 | Roxybond |
| Hikma Pharmaceuticals USA | $41.46 | 2022 | |
| Vision Quest Industries INC. | $39.24 | 2022 | |
| Averitas Pharma INC. | $38.46 | 2024-2025 | Qutenza |
| Allergan, INC. | $37.43 | 2022 | |
| Vertos Medical, INC. | $35.75 | 2023-2024 | Mild Device Kit |
| Axsome Therapeutics, INC. | $32.67 | 2025 | Symbravo |
| Zimmer Biomet Holdings, INC. | $24.40 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Azurity Pharmaceuticals, INC. | $21.78 | 2023 | Horizant |
| Convatec INC. | $19.55 | 2025 | |
| Collegium Pharmaceutical, INC. | $15.76 | 2023 | Belbuca |
| Ibsa Pharma INC. | $15.39 | 2022 | |
| Athena Bioscience, LLC | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munish Loomba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.